These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30605489)

  • 21. Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease.
    Popov J; Zhukov O; Ruden S; Zeschmann T; Sferruzza A; Sahud M
    Clin Chem; 2006 Oct; 52(10):1965-7. PubMed ID: 16887898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe Aortic Valve Stenosis.
    Frank RD; Lanzmich R; Haager PK; Budde U
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):229-234. PubMed ID: 27481874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes.
    Tobin WO; Kinsella JA; Kavanagh GF; O'Donnell JS; McGrath RT; Tierney S; Egan B; Feeley TM; Coughlan T; Collins DR; O'Neill D; Murphy S; Lim SJ; Murphy RP; McCabe D
    J Neurol Sci; 2017 Apr; 375():404-410. PubMed ID: 28320178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.
    Pérez-Rodríguez A; Batlle J; Corrales I; Borràs N; Rodríguez-Trillo Á; Lourés E; Cid AR; Bonanad S; Cabrera N; Moret A; Parra R; Mingot-Castellano ME; Navarro N; Altisent C; Pérez-Montes R; Marcellini S; Moreto A; Herrero S; Soto I; Fernández Mosteirín N; Jiménez-Yuste V; Alonso N; de Andrés Jacob A; Fontanes E; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Castro Quismondo N; Iñigo B; Nieto MDM; Vidal R; Martínez MP; Aguinaco R; Tenorio M; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Dobón M; Aguilar C; Batlle F; Vidal F; López-Fernández MF
    PLoS One; 2018; 13(6):e0197876. PubMed ID: 29924855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.
    Stufano F; Baronciani L; Mane-Padros D; Cozzi G; Faraudo S; Peyvandi F
    Haemophilia; 2018 Jan; 24(1):156-161. PubMed ID: 29168270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
    Callan MB; Giger U; Catalfamo JL
    Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study.
    Favaloro EJ; Bonar R; Hollestelle MJ; Jennings I; Mohammed S; Meijer P; Woods T; Meiring M
    Thromb Res; 2018 Jun; 166():96-105. PubMed ID: 29727738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
    Favaloro EJ
    Methods Mol Biol; 2017; 1646():391-402. PubMed ID: 28804843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease.
    Jakob A; Schachinger E; Klau S; Lehner A; Ulrich S; Stiller B; Zieger B
    Eur J Pediatr; 2020 Mar; 179(3):377-384. PubMed ID: 31760507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical variant of acquired von Willebrand syndrome in Wilms tumor: is hyaluronic acid secreted by nephroblastoma cells the cause?
    Michiels J; Schroyens W; Berneman Z; van der Planken M
    Clin Appl Thromb Hemost; 2001 Apr; 7(2):102-5. PubMed ID: 11292185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated plasma von Willebrand factor and propeptide levels in Malawian children with malaria.
    Phiri HT; Bridges DJ; Glover SJ; van Mourik JA; de Laat B; M'baya B; Taylor TE; Seydel KB; Molyneux ME; Faragher EB; Craig AG; Bunn JE
    PLoS One; 2011; 6(11):e25626. PubMed ID: 22125593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.
    Favaloro EJ
    Semin Thromb Hemost; 2007 Nov; 33(8):727-44. PubMed ID: 18175279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.